Fasinumab Emerging Drug Insight and Market Forecast - 2032

“Fasinumab Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about fasinumab for knee osteoarthritis (OA) in the seven major markets. A detailed picture of the fasinumab for knee osteoarthritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the fasinumab for knee osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the fasinumab market forecast analysis for knee osteoarthritis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in knee osteoarthritis.

Drug Summary

Fasinumab (REGN475) is an investigational fully human IgG4κ monoclonal antibody in clinical development for OA and chronic low back pain. It is designed to target nerve growth factor (NGF), a protein that plays a central role in the regulation of pain signaling. There is evidence that NGF levels are elevated in the synovial fluid of patients with chronic pain conditions, and blocking NGF may reduce chronic low back pain (CLBP). It is under development by Mitsubishi Tanabe, Regeneron, and Teva to collaborate on the global development and commercialization of fasinumab. However, it was invented by Regeneron Pharmaceuticals using the company's proprietary VelocImmune technology that yields optimized fully-human antibodies.

Nerve growth factor (NGF) is one of the neurotrophins, a family of polypeptide growth factors that help regulate pathways of development, differentiation, survival, and death of neuronal and non-neuronal cells. NGF activity is mediated through two different membrane-bound receptors, the high-affinity tropomyosin receptor kinase A (TrkA) receptor and the low-affinity p75 common neurotrophin receptor. The NGF/TrkA system appears to play a major role in the control of inflammation and pain, and blockade of this pathway normalizes pain sensitivity. Fasinumab binds to NGF and blocks its signaling through TrkA and p75 receptors.

Mitsubishi Tanabe Pharma anticipatesthe launch of fasinumab (MT-5547) by 2023 in Japan.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the fasinumab description, mechanism of action, dosage and administration, research and development activities in knee osteoarthritis.
• Elaborated details on fasinumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the fasinumab research and development activities in knee osteoarthritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around fasinumab.
• The report contains forecasted sales of fasinumab for knee osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for knee osteoarthritis.
• The report also features the SWOT analysis with analyst views for fasinumab in knee osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Fasinumab Analytical Perspective

In-depth Fasinumab Market Assessment

This report provides a detailed market assessment of fasinumab for knee osteoarthritis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Fasinumab Clinical Assessment

The report provides the clinical trials information of fasinumab for knee osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for knee osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence fasinumab dominance.
• Other emerging products for knee osteoarthritis are expected to give tough market competition to fasinumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of fasinumab in knee osteoarthritis.
• Our in-depth analysis of the forecasted sales data of fasinumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the fasinumab in knee osteoarthritis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of fasinumab?
• What is the clinical trial status of the study related to fasinumab in knee osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the fasinumab development?
• What are the key designations that have been granted to fasinumab for knee osteoarthritis?
• What is the forecasted market scenario of fasinumab for knee osteoarthritis?
• What are the forecasted sales of fasinumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to fasinumab for knee osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of knee osteoarthritis?